Quoin Pharmaceuticals Files 8-K

TL;DR

Quoin Pharma filed an 8-K, but details are scarce. Keep an eye out.

AI Summary

Quoin Pharmaceuticals, Ltd. filed an 8-K on January 23, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or new developments. The company was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.

Why It Matters

This 8-K filing indicates a material event has occurred for Quoin Pharmaceuticals, Ltd., requiring disclosure to investors, though the specifics are not yet detailed.

Risk Assessment

Risk Level: medium — The filing of an 8-K often signals significant corporate events, but the lack of specific details in this report creates uncertainty.

Key Players & Entities

• Quoin Pharmaceuticals, Ltd. (company) — Filer of the 8-K
• January 23, 2025 (date) — Date of Report
• Cellect Biotechnology Ltd. (company) — Former company name
• Cellect Biomed Ltd. (company) — Former company name

FAQ

Filing Documents

• tm254263d1_8k.htm (8-K) — 30KB
• 0001104659-25-005619.txt ( ) — 198KB
• qnrx-20250123.xsd (EX-101.SCH) — 3KB
• qnrx-20250123_lab.xml (EX-101.LAB) — 33KB
• qnrx-20250123_pre.xml (EX-101.PRE) — 22KB
• tm254263d1_8k_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. Quoin Pharmaceuticals Ltd. (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome. In December 2024 and January 2025, Quoin announced positive data from the mid-point and at completion of 12 weeks of testing the first subject dosed twice-daily in Quoin's ongoing open-label study which demonstrated evidence of clear improvement across all measured clinical endpoints. Today Quoin is sharing additional data on that observed after 12 weeks of testing with QRX003 were completely reversed by 4 weeks after discontinuation of treatment resulting in the Table 1: First Patient Data from Open Label Study Part B- Dosed Twice Daily with QRX003 End Point Baseline 6 weeks (Treatment period midpoint) 12 weeks (End of treatment period) 4 weeks post discontinuation of treatment M-IASI* 18 4 3 18 WINRS** 7 4 2 8 IGA*** Moderate Mild Almost Clear Moderate * M-IASI : Modified Ichthyosis Area of Severity Index, a score used to assess the severity and extent of skin symptoms associated with ichthyosis. Lower scores indicate improvement. ** WINRS : Worst Itch Numeric Rating Scale, which measures the severity of itch on an 11-point scale (0 = no itch, 10 = worst imaginable itch). *** IGA : Investigator's Global Assessment, which uses descriptive categories (e.g., clear, mild, moderate, severe) to evaluate the overall severity of Netherton Syndrome symptoms.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: January 23, 2025 QUOIN PHARMACEUTICALS LTD. By: /s/ Michael Myers Name: Dr. Michael Myers Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR